Vinge advises Active Biotech in relation to directed new share issue
April 04, 2013
In March this year, Active Biotech AB (publ) conducted a directed new share issue to Investor AB (publ) pursuant to which Active Biotech procured SEK 270 million.
Vinge’s team consisted of partner Erik Sjöman and associate Christian Lindhé.
Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
